Alpha Glucosidase Inhibitors Market to record USD 567.96 Mn incremental growth -- Driven by increase in awareness of diabetes and growing initiatives

NEW YORK, Sept. 26, 2022 /PRNewswire/ -- The "Alpha Glucosidase Inhibitors Market by Disease Type and Geography - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years.

Technavio has announced its latest market research report titled Global Alpha Glucosidase Inhibitors Market 2022-2026
Technavio has announced its latest market research report titled Global Alpha Glucosidase Inhibitors Market 2022-2026

The potential growth difference for the alpha glucosidase inhibitors market between 2021 and 2026 is USD 567.96 million. The report identifies various factors including the prevalence rate of the disease, revenue generated by pharmaceutical companies, GDP growth, disposable income, and commodity price fluctuation among others to estimate the size of the market. Download PDF Sample Report

Key Market Dynamics:

  • Market Driver

  • Market Challenges

The increase in awareness of diabetes and growth initiatives are expected to drive the growth of the market. Government agencies and various organizations across the world are undertaking several community-level and global-level programs to tackle diabetes. For instance, in April 2021, the IDF and Direct Relief announced an initiative to supply diabetes products to vulnerable populations around the world. Similarly, The National Diabetes Services Scheme (NDSS) by the Australian Government along with Diabetes Australia focuses on enhancing the capacity of people with diabetes to understand and self-manage their condition. Diabetes Australia also seeks to support people with diabetes by providing timely, reliable, and affordable access to NDSS services. The presence of such awareness programs will drive the growth of the market during the forecast period.

In addition, the growing awareness of the benefits of alpha glucosidase inhibitors will further drive the growth of the market. However, price pressure and availability of counterfeiter drugs will challenge market growth.

The alpha glucosidase inhibitors market report is segmented by Geography (North America, Europe, Asia, and the Rest of the World (ROW)) and Disease Type (Type 2 diabetes and Dumping syndrome).

North America will dominate the market growth, occupying 42% of the global market share. The increasing prevalence of type 2 diabetes and dumping syndrome is driving the growth of the regional market.

By disease type, the market growth in the type 2 diabetes segment will be significant over the forecast period. The segment is driven by the high prevalence of type 2 diabetes.

View Our Sample Report for highlights on the contribution of various segments and regionals toward the market growth.

Key Companies Mentioned with their Offerings

  • Anderson Hay and Grain Co. Inc.: The company offers alpha glucosidase inhibitors such as alfalfa hay.

  • Bayer AG: The company offers alpha glucosidase inhibitors such as GLUCOBAY.

  • BioVision Inc.: The company offers various life sciences research tools required for drug discovery in disease-related areas like cancer, diabetes, obesity, Alzheimer's disease, etc.

  • Border Valley Trading: The company offers alpha glucosidase inhibitors for beef cattle, horses, sheep, goats, and camels.

  • Bristol Myers Squibb Co.: The company operates in a single segment and is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines for various diseases.

  • AstraZeneca Plc

  • C. H. Boehringer Sohn AG and Co. KG

  • Eli Lilly and Co.

  • GSK Plc

  • Glenmark Pharmaceuticals Ltd

  • Merck KGaA

  • Novartis AG

  • Novo Nordisk AS

  • Pfizer Inc.

  • Sanofi

  • Straight Healthcare

  • Sun Pharmaceutical Industries Ltd.

  • Takeda Pharmaceutical Co. Ltd.

Related Reports:

Alpha Glucosidase Inhibitors Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 2.51%

Market growth 2022-2026

USD 567.96 million

Market structure

Fragmented

YoY growth (%)

2.0

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key consumer countries

US, Germany, UK, China, and Japan

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Anderson Hay and Grain Co. Inc., AstraZeneca Plc, Bayer AG, BioVision Inc., Border Valley Trading, Bristol Myers Squibb Co., C. H. Boehringer Sohn AG and Co. KG, Eli Lilly and Co., GSK Plc, Glenmark Pharmaceuticals Ltd, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi, Straight Healthcare, Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of contents:

1 Executive Summary

  • 1.1 Market overview

2 Market Landscape

  • 2.1 Market ecosystem

3 Market Sizing

  • 3.1 Market definition

  • 3.2 Market segment analysis

  • 3.3 Market size 2021

  • 3.4 Market outlook: Forecast for 2021-2026

4 Five Forces Analysis

  • 4.1 Five forces summary

  • 4.2 Bargaining power of buyers

  • 4.3 Bargaining power of suppliers

  • 4.4 Threat of new entrants

  • 4.5 Threat of substitutes

  • 4.6 Threat of rivalry

  • 4.7 Market condition

5 Market Segmentation by Disease Type

  • 5.1 Market segments

  • 5.2 Comparison by Disease Type

  • 5.3 Type 2 diabetes - Market size and forecast 2021-2026

  • 5.4 Dumping syndrome - Market size and forecast 2021-2026

  • 5.5 Market opportunity by Disease Type

6 Customer Landscape

  • 6.1 Customer landscape overview

7 Geographic Landscape

  • 7.1 Geographic segmentation

  • 7.2 Geographic comparison

  • 7.3 North America - Market size and forecast 2021-2026

  • 7.4 Europe - Market size and forecast 2021-2026

  • 7.5 Asia - Market size and forecast 2021-2026

  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026

  • 7.7 US - Market size and forecast 2021-2026

  • 7.8 Germany - Market size and forecast 2021-2026

  • 7.9 UK - Market size and forecast 2021-2026

  • 7.10 China - Market size and forecast 2021-2026

  • 7.11 Japan - Market size and forecast 2021-2026

  • 7.12 Market opportunity by geography

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers

  • 8.2 Market challenges

  • 8.3 Impact of drivers and challenges

  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview

  • 9.2 Vendor landscape

  • 9.3 Landscape disruption

  • 9.4 Industry risks

10 Vendor Analysis

  • 10.1 Vendors covered

  • 10.2 Market positioning of vendors

  • 10.3 Anderson Hay and Grain Co. Inc.

  • 10.4 Bayer AG

  • 10.5 Border Valley Trading

  • 10.6 Eli Lilly and Co.

  • 10.7 Glenmark Pharmaceuticals Ltd

  • 10.8 Merck KGaA

  • 10.9 Pfizer Inc.

  • 10.10 Sanofi

  • 10.11 Sun Pharmaceutical Industries Ltd.

  • 10.12 Takeda Pharmaceutical Co. Ltd.

11 Appendix

  • 11.1 Scope of the report

  • 11.2 Inclusions and exclusions checklist

  • 11.3 Currency conversion rates for US$

  • 11.4 Research methodology

  • 11.5 List of abbreviations

 

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:media@technavio.com
Website: www.technavio.com/

Global Alpha Glucosidase Inhibitors Market 2022-2026
Global Alpha Glucosidase Inhibitors Market 2022-2026
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/alpha-glucosidase-inhibitors-market-to-record-usd-567-96-mn-incremental-growth--driven-by-increase-in-awareness-of-diabetes-and-growing-initiatives-301632046.html

SOURCE Technavio